IP Library › Granted Patent US 10,022,421
Granted Patent B2
US 10,022,421 · App. 15/061,821 · Granted Jul 17, 2018

Treatment of primary and metastatic carcinoma

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,022,421
App. No.
15/061,821
Granted
Jul 17, 2018
Kind
B2
Abstract

Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ET B ) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.

Claims (11)

1. A method of treating a metastatic chemotherapy-resistant cancer, wherein said cancer comprises tumors comprising blood vessels expressing ET B receptors, said method comprising: administering a therapeutically effective amount of an endothelin B (ET B ) receptor agonist and a therapeutically effective amount of chemotherapeutic agent to a subject suffering from a chemotherapy-resistant cancer; wherein the ET B receptor agonist is IRL-1620 and wherein administration results in a reduction in the size or in the growth of the chemotherapy-resistant cancer, thereby treating the chemotherapy-resistant cancer.

2. The method of claim 1 , wherein the therapeutically effective amount of IRL-1620 is about 5 μg/m 2 to about 11 μg/m 2 .

3. The method of claim 1 , wherein the chemotherapeutic agent is a docetaxel.

4. The method of claim 1 , wherein the chemotherapy resistant cancer being treated is a prostate, breast, or ovarian cancer.

5. The method of claim 1 , wherein the cancer being treated is unresponsive to prior taxane chemotherapy.

6. The method of claim 3 , wherein the therapeutically effective amount of docetaxel is about 60 mg/m 2 to about 75 mg/m 2 .

7. The method of claim 3 , wherein the therapeutically effective amount of docetaxel is about 60 mg/m 2 .

8. The method of claim 1 , wherein the ET B receptor agonist and the chemotherapeutic agent are administered substantially simultaneously.

9. The method of claim 4 , wherein the chemotherapy-resistant cancer being treated is a prostate cancer.

10. The method of claim 4 , wherein the chemotherapy-resistant cancer being treated is a breast cancer.

11. The method of claim 4 , wherein the chemotherapy-resistant cancer being treated is an ovarian cancer.

Assignments (3)
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 061179/FRAME 0202 Recorded Aug 1, 2023
From: SLR INVESTMENT CORP.
To: SPECTRUM PHARMACEUTICALS, INC.; ALLOS THERAPEUTICS, INC.; TALON THERAPEUTICS, INC.
Reel/Frame 064463/0709 →
SECURITY INTEREST Recorded Sep 22, 2022
From: SPECTRUM PHARMACEUTICALS, INC.; ALLOS THERAPEUTICS, INC.; TALON THERAPEUTICS, INC.
To: SLR INVESTMENT CORP., AS COLLATERAL AGENT
Reel/Frame 061179/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2016
From: TOLCHER, ANTHONY W; LENAZ, LUIGI
To: SPECTRUM PHARMACEUTICALS, INC.
Reel/Frame 037898/0688 →